- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04461405
INTEGRATE-D: A Pilot Test to Support Integration of Medical and Psychosocial Care for People With Type II Diabetes
November 12, 2023 updated by: Deborah Cohen, Oregon Health and Science University
INTEGRATE-D: A Pilot Test of Implementation Strategies to Support Integration of Medical and Psychosocial Care for People With Type II Diabetes
In 2016, the American Diabetes Association (ADA) published its first-ever recommendations for integrating medical and psychosocial care for patients with Type II Diabetes Mellitus (DMII) and common mental and behavioral health (MH/BH) problems.
In the United States, 30 million people live with DMII, and the majority receive care in primary care settings.
By implementing the ADA recommendations, primary care practices will help patients better manage their MH/BH needs, meet recommended goals for DMII management, and reduce the risk of adverse outcomes.
Making these recommendations a routine part of practice is a major change, and it is critical to understand how best to implement the ADA recommendations and test its effectiveness in the real world.
The pilot study builds on a series of prior studies to refine and pilot test a package of implementation strategies - called INTEGRATE-D - to support practices in implementing the ADA recommendations for integrated DMII care.
INTEGRATE-D combines the following evidence-based implementation strategies: (1) electronic health record (EHR)-based support - to help align EHR use with ADA recommendations and enable screening for depression, anxiety, diabetes distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback - which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources - including training on ADA-recommended care; and (4) Facilitation - to help implement the above strategies and tailor the intervention so that practice work on the subset of areas where practices are ready to change to align care with ADA recommendations.
The study aims are Aim 1: Refine the INTEGRATE-D intervention by incorporating the preferences of stakeholders.
In partnership with patients, primary care key stakeholders and experts, compile and refine the package of implementation strategies in the INTEGRATE-D intervention.
Aim 2: Demonstrate feasibility, acceptability, and estimate cost.
Conduct a mixed-method, pre-post pilot comparing two practices that receive the INTEGRATE-D intervention to two control practices that receive training materials only.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The INTEGRATE-D intervention is designed to support primary care practices with implementing ADA recommendations for integrating medical and psychosocial care for patients with DMII.
Primary care practices will be the recipients of this support.
For practices, the intervention will be 15 months long.
The first three months will be a "Readiness Phase" where the study team assesses practices' capacity at baseline and a facilitator works with intervention practices to address capacity issues (e.g., help the practice produce a quality report) that can be barriers during active implementation.
Then, intervention practices receive 12 months of "Active Intervention" with the same facilitator to align care processes with ADA recommendations.
Pilot study design: The study team will use a randomized, mixed-method, pre-post design for this pilot study.
The goal of this randomized pilot design is to evaluate the feasibility of recruitment, randomization, retention, assessment procedures, implementation of the INTEGRATE-D intervention, and provide insights into the effect of this pilot intervention on practice-level outcomes.
Practice Sample and eligibility criteria: The sample for this pilot is four primary care practices.
Practices with more than 100 adult patients (≥18 years) with a diagnosis of DM (Type II; not gestational) are eligible.
Practice Recruitment: Practices will be recruited from the ORPRN practice-based research network.
ORPRN works with 279 primary care practices in the state of Oregon, including 51% that are rural and 42% clinician-owned practices.
ORPRN recruiters will identify 50 potential practices and conduct a faxback to assess interest, capacity, and eligibility.
Of interested practices, ORPRN and the study team will select 4 practices (2 rural and 2 non-rural) that vary on whether practices employ a behavioral health clinician.
The study team will purposefully vary practices on these characteristics based on previous work that demonstrated they influenced intervention uptake.
Patient Sample: The study team will have three different patient samples.
For chart audits, there will be two samples.
(1) Patients with a diagnosis of DMII who have been seen at least once at the practice in the 15 months prior to the intervention start date and at least once after the intervention start date will be included in the chart audit.
The study team will randomly select 50 patients meeting these criteria.
(2) Patients meeting the above criteria and screening positive for depression (i.e., those patients who have minimally exposed to the INTEGRATE-D intervention will also be randomly selected for chart audit.
The study team will audit charts until there is a sample of 30 patients meeting these criteria.
(3) From this latter group, the study team will select 5 patients at each of the two intervention practices to participate in an interview.
Randomization Procedure: Practices will be randomized in a 1:1 ratio through a covariate-constrained randomization procedure.
This is accomplished as follows.
Prior to randomization, the study team will collect baseline data on practice-level factors (e.g., practice size, ownership, rurality, patient panel demographics, etc.) that could influence process and outcome measures.
These data will be collected as part of the recruitment process.
The study team will construct all possible combinations of eligible practices into two groups.
For each selected possible randomization, the study team will compare the balance between study arms in the important baseline data described above through a balance criterion.
The study team will randomly select one randomization combination (from the 2 combinations with the best balance) which will yield 2 practices in each study arm with good balance in important covariates.
Data Collection: For this pilot study, the study team will collect mixed methods (survey, observation, interview, and chart audit) data.
For control practices, data collection will include the collection of survey and chart audit data.
These data will be collected at the same time as data collected from intervention practices.
Intervention practices, in addition to completing surveys and participating in the chart audit, will participate in practice site visits, which include the study team observing the practice and how it delivers care and interviewing a varied group of practice members, including those that participated in implementing the intervention.
These visits will happen before and after the intervention.
In addition, during the implementation of INTEGRATE-D, the study team will conduct monthly telephone calls with a key informant at the intervention practices.
Measures: The study team will measure practice capacity for quality improvement using the Change Process Capability Questionnaire (survey).
The study team will measure changes in care processes, as follows: for depression - screening for depression using the Patient Health Questionnaire (PHQ)-9, rates of referral to behavioral health when patients screen positive on the PHQ-9; for diabetes - the study team will use a composite measure of DMII process of clinical care (e.g., screening for HbA1c, eye, and foot exams) and assess discussion of and engagement in self-management activities (e.g., healthy eating, physical activity).
The study team will measure outcome change as a change in PHQ-9 and HbA1c.
All process and outcome measures will all be collected via chart audit.
The study team will measure feasibility and acceptability, perceived and actual, of INTEGRATE-D using observation, semi-structured interviews, survey, and facilitator tracking data.
Surveys will use validated acceptability and feasibility measures.
Statistical power: As this is a pilot study, it is not meant to have the sample size needed to test for statistical significance.
Rather, this pilot is designed to show the promise of the INTEGRATE-D intervention and provide the data need to do accurate power calculations for the larger, subsequent pragmatic trial.
Data Analysis.
Qualitative analysis will follow a rigorous process whereby a team of experienced qualitative researchers will identify emerging patterns or findings, and then analyze data again to solidify these patterns into a coherent set of findings.
Quantitative analyses will use standard descriptive statistical methods and the study team will utilize Generalized Linear Mixed Models to compare the effect of INTEGRATE-D intervention on process outcome measures in the context of a cluster-randomized design.
Study Type
Interventional
Enrollment (Actual)
294
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria
In order for patients to become eligible, their primary care practice must meet the following inclusion criteria:
- Primary care practices are affiliated with the Oregon Rural Practice-Based Network (ORPRN), at time of recruitment.
- Primary care practices must be located in Oregon.
- Primary care practices have more than 100 adult patients aged 18 years or older with an electronic health record-based diagnosis of Type II Diabetes Melitus (DMII).
Once the criteria for a primary care practice is satisfied, the inclusion criteria for DMII patients includes the following:
- Patients are 18 years of age or older.
- Patients have an electronic health record-based diagnosis of DMII.
- Patients were seen by an ORPRN practice at least once in the 15 months prior to the start of intervention and once during the intervention.
Exclusion Criteria
Primary care practices that do not meet the inclusion criteria established are not eligible for the pilot study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Arm
INTEGRATE-D is a step-by-step blueprint that will assist practices with employing American Diabetes Association recommendations for integrating medical and psychosocial care.
INTEGRATE-D consists of a set of implementation strategies that enable clinical teams to put evidence-based care in place.
The intervention consists of training and education; audit and feedback materials; a facilitation implementation protocol; and health information technology support materials.
|
INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
|
No Intervention: Control Arm
Usual care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of intervention
Time Frame: At 15 months, post-intervention
|
A post-intervention four-item survey that evaluates the extent to which the intervention meets practice members' approval, is appealing and is liked and welcomed.
The items will be assessed on a Likert scale, ranging from 1 to 5 (i.e., completely disagree to completely agree).
Composite scores will be created.
|
At 15 months, post-intervention
|
Appropriateness of the intervention
Time Frame: At 15 months, post-intervention
|
A post-intervention four-item survey that evaluates the extent to which the intervention is fitting, suitable, applicable, and seems like a good match.
The items will be assessed on a Likert scale, ranging from 1 to 5 (i.e., completely disagree to completely agree).
Composite scores will be created.
|
At 15 months, post-intervention
|
Feasibility of the intervention
Time Frame: At 15 months, post-intervention
|
A post-intervention four-item survey that evaluates the extent to which the intervention is implementable, seems possible, seems doable, and seems easy to use.
The items will be assessed on a Likert scale, ranging from 1 to 5 (i.e., completely disagree to completely agree).
Composite scores will be created.
|
At 15 months, post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin A1c
Time Frame: Change from baseline screening at 15 months
|
Measure of average blood sugar
|
Change from baseline screening at 15 months
|
Patient Health Questionnaire-9
Time Frame: Change from baseline screening at 15 months
|
The nine-item validated screener measures depression severity.
Questionnaire items are on a Likert scale and range from 0 (i.e., not at all) to +3 (i.e., nearly every day), and the total score ranges from 0 (i.e., minimal to none) to 27 (i.e., severe).
|
Change from baseline screening at 15 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2020
Primary Completion (Actual)
June 1, 2022
Study Completion (Actual)
June 1, 2022
Study Registration Dates
First Submitted
June 26, 2020
First Submitted That Met QC Criteria
July 1, 2020
First Posted (Actual)
July 8, 2020
Study Record Updates
Last Update Posted (Estimated)
November 14, 2023
Last Update Submitted That Met QC Criteria
November 12, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20783
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Health Care
-
Veteran Affairs Office of Patient Care ServicesVA Office of Research and Development; VA Palo Alto Health Care System; VHA Primary...CompletedPrimary Health Care | Health Care CostsUnited States
-
Veteran Affairs Office of Patient Care ServicesVA Office of Research and Development; VA Palo Alto Health Care System; VHA Primary...CompletedPrimary Health Care | Health Care Costs
-
VA Office of Research and DevelopmentVA Palo Alto Health Care System; Veteran Affairs Office of Patient Care ServicesCompletedPrimary Health Care | Health Care Costs
-
University of CoimbraCompletedPalliative Care | Primary Health CarePortugal
-
Bert LeysenIntermutualistic Agency; National Institute for Health and Disability Insurance...CompletedPalliative Care | Primary Health CareBelgium
-
Wellington-Dufferin-Guelph Public HealthBoston Medical Center; University of Guelph; East Wellington Family Health Team; Minto-Mapleton Family Health Team and other collaboratorsCompletedPrimary Health Care | Health Information Technology | Risk Assessment | Preconception CareCanada
-
University of Colorado, DenverCompletedPrimary Health Care | Advance Care PlanningUnited States
-
Université de SherbrookeIsabelle Gaboury; Mike Green; Tara Kiran; Janusz Kaczorowski; Maude LabergeRecruiting
-
The University of Hong KongCompleted
-
Oregon Health and Science UniversityCompletedPrimary Health Care | Health Services | ComorbidityUnited States
Clinical Trials on INTEGRATE-D
-
Cedars-Sinai Medical CenterRecruitingCancer | SurvivorshipUnited States
-
Chung Shan Medical UniversityCompleted
-
University of California, Los AngelesUniversity of California, San Diego; California HIV/AIDS Research Program; Los... and other collaboratorsCompletedHIV PreventionUnited States
-
Lee's Pharmaceutical LimitedUnknownOvarian Epithelial Cancer | Fallopian Tube Cancer | Primary Peritoneal CancerChina
-
Rhode Island HospitalVirtually Better, Inc.CompletedMental Health | Human Immunodeficiency VirusUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy VolunteersFrance
-
Royal Prince Alfred Hospital, Sydney, AustraliaCompleted
-
GlaxoSmithKlineCompleted
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting